# The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan

> **NCT03912350** · PHASE1 · WITHDRAWN · sponsor: **Hoffmann-La Roche**

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** Balovaptan

## Key facts

- **NCT ID:** NCT03912350
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-06-26
- **Primary completion:** 2022-09-24
- **Final completion:** 2022-10-13
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study is on hold due to stopping of the Autism Spectrum Disorder program with balovatpan, the study drug.
- **Last updated:** 2022-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03912350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03912350, "The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03912350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*